EXO-CD24 by Nano24med for Acute Respiratory Distress Syndrome: Likelihood of Approval

EXO-CD24 is under clinical development by Nano24med and currently in Phase II for Acute Respiratory Distress Syndrome.

Paxlovid treatment in 20% of COVID-19 patients could avert 850,000 hospitalizations, save up to $170 billion

A study in the Emerging Infectious Diseases journal shows treating 20% of COVID-19 patients with Paxlovid could save up to 0.85 million lives and reduce

January 15, 2024

A new moonshot initiative to fight cervical cancer in the Indo-Pacific region is missing something

A few weeks ago, President Joe Biden and the leaders of Australia, India, and Japan gathered at Biden’s home in Delaware to announce to much

November 29, 2024

Conservative justices stir trouble for Republican politicians on abortion

Abortion opponents have maneuvered in courthouses for years to end access to reproductive health care. In Arizona last week, a win for the anti-abortion camp

April 16, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.